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ABSTRACT
Introduction: Motor neuron disease (MND) is a
terminal, progressive, multisystem disorder. Well-timed
decisions are key to effective symptom management.
To date, there are few published decision support
tools, also known as decision aids, to guide patients in
making ongoing choices for symptom management
and quality of life. This protocol is to develop and
validate decision support tools for patients and families
to use in conjunction with health professionals in MND
multidisciplinary care. The tools will inform patients
and families of the benefits and risks of each option,
as well as the consequences of accepting or declining
treatment.
Methods and analysis: The study is being
conducted from June 2015 to May 2016, using a
modified Delphi process. A 2-stage, 7-step process
will be used to develop the tools, based on existing
literature and stakeholder feedback. The first stage will
be to develop the decision support tools, while the
second stage will be to validate both the tools and the
process used to develop them. Participants will form
expert panels, to provide feedback on which the
development and validation of the tools will be based.
Participants will be drawn from patients with MND,
family carers and health professionals, support
association workers, peak body representatives, and
MND and patient decision-making researchers.
Ethics and dissemination: Ethical approval for the
study has been granted by Macquarie University
Human Research Ethics Committee (HREC), approval
number 5201500658. Knowledge translation will be
conducted via publications, seminar and conference
presentations to patients and families, health
professionals and researchers.
INTRODUCTION
Motor neuron disease (MND), also known as
amyotrophic lateral sclerosis, is a terminal,
progressive, multisystem disorder. Incidence
worldwide is estimated at 2–3 per 100 000 of
total population.1 Approximately 1500
people are currently living with MND in
Australia. There is, as yet, no cure, and treat-
ment options offer little extension to life
expectancy. The cause of the disease remains
unknown. MND is a heterogenic condition,
with a range of clinical presentations, or phe-
notypes.2 3 Survival time varies with pheno-
type, averaging around 3 years.4 Death most
frequently results from respiratory failure.5
Patients experience physical deterioration
that frequently affects their mobility, swallow-
ing and speech. Deterioration of patients’
physical status may be accompanied by
changes to their cognitive skills and behavi-
our.6 Around 50% of patients are thought to
be affected by mild cognitive or behavioural
change.7 Cognitive change may present as
frontotemporal dementia or, more fre-
quently, as mild cognitive change affecting
capacity to control and regulate cognitive
process such as memory and information
processing skills.2–8 Behavioural change is
characterised by apathy and impulsivity.8 The
complexity of MND creates a challenging
environment for patient care.
Treatment approaches for this complex
condition are palliative in nature. They
include disease-slowing medication and artiﬁ-
cial support for respiration, feeding and
Strengths and limitations of this study
▪ A user-centric approach to decision support tool
development will result in tools that address the
needs of patients with motor neuron disease
(MND), carers and health professionals.
▪ As the modified Delphi process is iterative and
consultative, consensus between panel members
may take time to achieve.
▪ A comprehensive review of published and grey
literature in the MND and patient decision-
making fields will be undertaken. However, this
will not be conducted as a systematic literature
review.
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hydration. Care received through specialised multidiscip-
linary clinics has also been demonstrated to promote
survival.9 Patients and families are typically able to access
a range of medical, nursing, allied health clinicians and
support association staff within the multidisciplinary
clinic during a single visit. Patients with MND and fam-
ilies are asked to make numerous decisions for symptom
management and quality of life as the disease pro-
gresses. These decisions often involve consultation with
a range of health professionals before patients decide
how they wish to proceed.10 Moreover, due to the high
burden of physical care and emotional support required,
family members are frequently involved in patients’
decision-making process.11 Patients’ decision-making is
complicated by ongoing deterioration, psychological dis-
tress, changing psychosocial circumstances,12 and
deﬁned time frames for medical and surgical interven-
tion. Decisions are often delayed when patients and fam-
ilies experience difﬁculty engaging with health
professionals to discuss symptom management.13
The progressive nature of MND, and the range of
physical and intellectual functions it compromises,
creates an urgency for patients and families to under-
stand, and respond to, complex medical and health
service information. Patients and family members favour
healthcare information from sources they trust, such as
MND support associations, health professionals and
research-based websites.11 Moreover, health professionals
support the use of evidence-based information sources
to assist patients to make realistic and informed deci-
sions.14 Not surprisingly, patients with MND and families
report feeling overwhelmed by the amount and con-
fronting nature of information required for symptom
management decisions.11–15 However, poorly timed deci-
sions compromise patient health, safety and quality of
life, increase carer burden, and can result in costly and
distressing emergency hospital admissions.16 In these cir-
cumstances, the stress for patients, carers and health
professionals is signiﬁcant, and potential for problems
and less than optimal care increases.17
Decision support tools, also known as decision aids,
are used in a range of healthcare conditions18 to guide
patients through treatment decisions. Typically, such
tools have four components. They summarise
evidence-informed and best practice options; present
patients and families with the risks and beneﬁts of the
choices available to them;19 check patients’ understand-
ing of their options; and clarify personal values and pre-
ferences that inﬂuence choices, such as use of
treatments artiﬁcially extending life. Tools assist patients
to discuss their options with family and health profes-
sionals, understand the consequences of accepting or
declining treatment, and make informed choices for
care. There is also potential to facilitate safer and more
cost-effective care.16 By further improving patient partici-
pation in care discussions, use of the tools may optimise
the timing and effectiveness of care decisions.20 When
used during a care consultation, tools facilitate
communication between patients, family members and
health professionals, as well as allowing clinicians to
tailor tools and decisions to patients’ individual
circumstances.21
Currently, in the MND ﬁeld, there are few decision
support tools providing structured guidance to patients
and family carers for symptom management and quality
of life considerations. Owing to the unique MND disease
characteristics and trajectory, none of the existing tools
from deteriorating conditions such as cancer22 or
chronic disease23 are appropriate for symptom manage-
ment. As MND is a terminal condition lacking a cure,
and with limited disease-delaying options, decision-
making frequently becomes a choice between a single
treatment option, or doing nothing. MND decision
support tools need to inform patients on key decisions
that relate speciﬁcally to MND management, such as the
use of disease-slowing medication, the timing windows of
gastrostomy insertion in rapidly progressive disease.
While many of the equipment and procedures used to
manage MND are common to other conditions, the
timing, risks and beneﬁts are very speciﬁc to the indivi-
dual’s disease course. Moreover, there is little evidence
available to support most of the options. The value of
these tools is in preparing patients to consider their
values and preferences as they encounter disease
milestones.
By drawing on stakeholder consultation, user-centred
design principles,24 and guided by the International
Patient Decision Aids Standards (IPDAS),25 this project
will develop evidence-informed MND-speciﬁc tools to
support patients’ key symptom management and quality
of life decisions.26 27 Tools may include use of disease-
slowing medication, respiration support, artiﬁcial nutri-
tion and hydration, saliva management, and end-of-life
care.28 29 The study aims are to produce decision
support tools to meet the needs of patients with MND
attending Australian multidisciplinary clinics. The tools
will be designed as encounter tools; that is, tools for use
in a multidisciplinary clinic appointment between
patient, health professional and family carers. The
purpose of the tools is to support patients to clarify their
information needs, values and preferences before their
decision is made. We will examine the following research
questions (RQ):
RQ1. Which decision-making tools are needed to
support patients with MND?
RQ2. What is the optimal content and format of these
tools?
METHODS AND ANALYSIS
This research protocol details the process of develop-
ment and validation of decision support tools for specia-
lised MND multidisciplinary care. The study will be
conducted over 12 months, from June 2015 to May 2016.
Information to develop and validate decision support
tools will be gathered from published and grey
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literature, and through a modiﬁed Delphi process.30
Expert panels will be formed from participants with
experience in MND and/or patient decision-making.
The deliberation and development process will be con-
ducted electronically to include stakeholders from a
range of locations, and to create an open forum for dis-
cussion between participants. The decision tools will be
underpinned by research literature, and developed
according to feedback received from the expert panels.
Participants
Participants will be recruited from seven stakeholder
groups key to MND and patient decision-making,31 to
form two expert panels, one for patients and carers, and
one for health professionals and researchers. Use of sep-
arate panels will ensure patient and carer views on the
decision support tools are independent clinician and
researcher views. Views of the two panels will be inte-
grated to contribute to tool development. The role of
panel members will be to provide insight on key treat-
ment and quality of life decisions. To optimise stake-
holder representation, panel members will be sought
purposively, to contribute according to their experience
or expertise in MND or patient decision-making.
Potential participants will include patients with mid-
stage or late-stage disease who have experienced
decision-making for their care; and family members of
current or deceased patients who were involved in the
patient’s decision-making. Patients experiencing mild
cognitive and behavioural change, or early-stage fronto-
temporal dementia, who are able to give informed
consent (as advised by clinicians and advisors from the
recruitment settings) will be invited to participate.
Inclusion of patients with cognitive and behavioural
change will allow their views to shape the tools for the
requirements of this clinically diverse population.
However, patients with advanced frontotemporal demen-
tia who are unable to give informed consent will be
excluded from the study. Their carers will be invited to
give perspective on the needs of this subgroup.
Participants for the health professional and researcher
panel experienced health professionals working in MND
multidisciplinary care; MND regional advisors with
extensive experience in supporting patients and families;
representatives from the MND peak body (MND
Australia); MND clinical care researchers; and research-
ers with expertise in patient decision-making and deci-
sion support tool development. Researchers will include
a human factors engineer to ensure that the tools are
developed to meet users (ie, patients, carers and health
professionals) physical and psychological needs.24
Recruitment
Recruitment will be conducted through three healthcare
and research networks. First, a metropolitan specialised
MND multidisciplinary clinic will be accessed by the
study team. Patients with MND, carers and health profes-
sionals will be approached in person, and invited to
participate. Second, patients, carers and MND support
workers and a peak body representative will be recruited
through MND New South Wales (MND NSW) and MND
Australia. A recruitment letter will be forwarded to the
association inviting staff to take part in the project. MND
NSW staff will be asked to pass on study information to
patients and carers they consider suitable to participate
in the project. Third, researchers from the ﬁelds of MND
clinical care and patient decision-making will be con-
tacted by email through the study team’s international
research networks. All participants will be asked to give
written consent prior to participation on the expert
panel, and be available to complete assessments and
respond to discussion topics during the study period.
Expert panel consultation process
Overview
The project will be conducted using a two-stage modi-
ﬁed Delphi process of development and validation
(table 1). As encounter tools, they will be designed for
use by patients, carers and health professionals within
clinical appointments at specialised MND multidisciplin-
ary clinics. The process will involve iterative consultation,
expected to involve a minimum of four cycles, to opti-
mise participant feedback. Participants will ﬁrst be asked
to nominate decision tool topics for clinical care they
consider most useful. These will be developed into drafts
by the study team. Panel members will then be provided
with tool drafts and asked to provide feedback. The feed-
back will be used to reﬁne the tools, which will then be
returned to panel members for further comment and
reﬁnement. Once the panel agrees that the draft is com-
plete, the panel will validate the tools, and a prototype
will be ﬁnalised by the study team. The development
and validation stages of the project are described in
detail below.
Stage 1: tool development
The tool development stage will consist of four steps.
Step A will be a literature review to compile evidence-
based and best practice information on MND symptom
management, and decision tool development pro-
cesses.32 33 Healthcare databases, including MEDLINE,
the Cochrane Database, PsychINFO and grey literature,
will be searched, using terms that capture key con-
structs of the study. Terms will include decision support
tools, decision aids, choice behaviour, shared decision
making, health communication, motor neuron(e)
disease, amyotrophic lateral sclerosis and neurodegen-
erative disease. Patient information literature, such as
that provided by MND associations and health policy
documents, will also be sourced.
The tools will be checked against the IPDAS to ensure
tools comply with international best practice standards
as they are developed.25 The IPDAS criteria provide a
framework to evaluate both the content of decision tools
and the processes that are used to develop them.
Moreover, the criteria emphasise stakeholder
Hogden A, et al. BMJ Open 2016;6:e010532. doi:10.1136/bmjopen-2015-010532 3
Open Access
group.bmj.com on April 7, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
involvement in development and testing. Formats suit-
able for patient use within the MND multidisciplinary
clinic setting will be determined, that is, paper34 and
electronic35 formats. Paper tools will follow the Ottawa
Hospital Research Institute (OHRI) guidelines,36 while
electronic tools will be guided by similar exemplar
formats that are certiﬁed by IPDAS. The feasibility of
phone app37 formats will also be scoped by the study
team. A period of up to 4 months has been allocated to
this step.
Step B will be to form the expert panel, using the par-
ticipant recruitment process described above. Once the
panel has been assembled, members will be provided
with further education on the aims of the project, their
roles, and timeframes of the consultation and feedback
process. Participants will be informed about the use of
IPDAS criteria to ensure the evidence base, quality and
relevance of decision support tools. Forming and edu-
cating the expert panel is expected to take up to
2 months.
Table 1 Tool development and validation process summary
Step Objective Method
Timeline
(months) Process
Stage 1: tool development
A 1. Identify evidence-informed
and best practice
information for MND
symptom management
and quality of life issues
2. Identify decision tool
development processes
Literature review of:
▸ MND symptom management
▸ Quality of life issues
▸ Decision tool development
processes
▸ User-centred design
1–4 ▸ Determine evidence base and user
perspectives from literature
▸ Gain ethics approval
B Form expert panel ▸ Recruitment and selection of
expert panel members from
stakeholder groups
▸ Identify user priority list of
tools to be developed
4–5 Education of panel members on
participation, role requirements and
IPDAS criteria
C Development of tool drafts ▸ Expert panel consultation
▸ Delphi process
5–9 ▸ Nomination of five highest priority
tools
▸ Develop tool drafts
▸ Iterative consultation with panel
members as development
progresses
▸ Feedback loop with panel
members
D Final review of draft tools ▸ Expert panel review
▸ Evaluation against IPDAS
criteria
10 ▸ Consultation with panel members
▸ IPDAS checklist
Stage 2: validation process
E Validation of tool prototypes ▸ Expert panel agreement
▸ Study team consensus
10–11 ▸ Signoff by panel members
▸ Study team discussion
F Refinement and validation of
tool development process
▸ Feedback from panel
members on development
process
▸ Documentation of
development process
▸ Validation of process by expert
panel and study team
11 ▸ Formal mapping and
documentation of the development
process actually used in the study.
▸ A draft of this document will be
circulated to the expert panel.
▸ The expert panel will be asked to
give feedback on ways the process
could have been improved.
▸ The process will then be refined
according to participant feedback.
▸ The process will be documented
for knowledge translation.
G Knowledge translation ▸ Reporting to HREC
▸ Reporting to funding body
▸ Feedback to participants
▸ Publication of study findings
12 ▸ Written reports
▸ Newsletter to participants via email
▸ Peer-reviewed journal publication
▸ Seminar presentations
HREC, Human Research Ethics Committee; IPDAS, International Patient Decision Aids Standards; MND, motor neurone disease.
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Step C is the development of the highest priority tools
into draft form. Discussions with expert panel members
will begin immediately after recruitment. This is to
ensure that patients, carers and health professionals, as
users of decision support tools, are included in a feed-
back loop from the beginning of the development
process. Once participants have been educated about
project requirements, the panel will be asked to gener-
ate a list of tools that they consider high priority to
MND clinical care, aligned with IPDAS criteria and
evidence-based literature.
A modiﬁed Delphi process will be applied, asking the
panel to nominate the ﬁve most useful tools for clinical
care, from user perspectives.33 These ﬁve tools will be
developed into paper drafts, by an iterative process of
review and reﬁnement. It is anticipated that four cycles
per tool will be necessary. A period of 1 week is allowed
for each cycle. Expert panel members will be sent tool
drafts by email, and asked to provide feedback in line
with their experience and expertise. Electronic commu-
nication will enable regular, documented group
comment on each draft. Participants will be asked to
reply to all the members of the panel and study team to
create an open forum for feedback. To facilitate and
structure comments, the study team will use a discussion
guide, based on the literature and the study team’s clin-
ical expertise. Participants will be asked to comment on
issues of: design; information content; readability;
format; and optimal timing of use between patients,
carers and health professionals. Five months has been
allocated for the production of draft tools.
Step D will be conducted once the ﬁve draft tools
have been completed. The expert panel and study team
will be asked to give a ﬁnal review of the drafts, and
check their content and development against the IPDAS
criteria. Group discussion will be used to resolve dis-
putes, solve problems and reach consensus on ﬁnal
drafts. Once agreement has been reached on the
content and format of the tools, the development stage
of the drafts will be complete. From this point, the tools
will be termed prototypes. A period of up to 1 month
has been set aside to complete this step.
Stage 2: tool validation
In step E, the expert panel will be asked to validate tool
prototypes by certifying that the prototypes are appropri-
ate for testing in the MND multidisciplinary care clinical
environment. Panel agreement on the prototypes will be
documented. The study team will also be asked to reach
consensus on the prototypes, using the group discussion
process described in step D. Once agreement is reached,
the prototypes will be considered validated. Two weeks
has been set aside for this step.
Reﬁnement and validation of the process used to
develop the decision tools occurs in step F, over the
period of a month. The development process used in
the study will be formally documented, and a draft will
be circulated to the expert panel for feedback on ways
the process could have been improved. The process will
be reﬁned according to participant feedback, and docu-
mented for dissemination.
Step G is the ﬁnal stage of development and valid-
ation, by knowledge translation. Taking place in the
ﬁnal month of the project, knowledge dissemination
and translation will be conducted reporting to the
funding body and the Macquarie University Human
Research Ethics Committee (HREC). Journal articles
will be prepared for peer review, and seminar presenta-
tions will be organised for academic and industry audi-
ences. The peer review process will further contribute
to the validation of the tool prototypes and develop-
ment process.
ETHICS AND DISSEMINATION
Ethical approval for the study has been granted by
Macquarie University HREC, approval number
5201500658. Recruitment ﬂyers and information sheets
summarising the study and the role of participants, as
well as consent forms, were also approved. Management
of participant information will be conducted in accord-
ance with Macquarie University guidelines; that is, all
personal information will be de-identiﬁed and kept in
password-protected electronic ﬁles. Information will be
destroyed after a minimum of 7 years.
Research dissemination and knowledge translation will
be conducted in three ways. Participants will be provided
with a summary of the process and outcomes of the
research. Results will be published in peer-reviewed pub-
lications, targeting healthcare service and decision-
making journals. Conference and seminar presentations
will be given to the Australian and international MND
research community, in accordance with funding body
agreement. Subject to funding availability, this study will
be extended for further research. Future projects aim to
implement the decision support tools in a range of
MND multidisciplinary clinics, evaluating the clinical
feasibility of the tools, and developing guidelines for use
in MND clinical care. Broader stakeholder input and
peer review will provide robust validation.
Decision support tools developed for MND care have
wider clinical application. At the conclusion of this
project, the study team will explore avenues to develop
decision support tools for a range of degenerative neuro-
logical conditions, including multiple sclerosis,
Parkinson’s disease and brain cancer. While speciﬁc
symptom management options will not be directly
applicable to other disease groups, the user-centric
process for developing the tools and formatting for
multidisciplinary clinical care will be adaptable for a
range of neurological conditions that currently lack deci-
sion support. The project has potential to be expanded
to countries and language groups beyond the Australian
context.
The innovation of this research is the production of
purpose-designed tools to improve MND patient care.
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The study has a multidimensional goal to advance
patient care, health professional teamwork, service deliv-
ery and policy development. The project seeks to
provide ﬁve signiﬁcant healthcare and research beneﬁts,
within Australia and internationally (table 2).
Twitter Follow Anne Hogden at @annehogden
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